Global Soliris (Eculizumab) Market Strategic Research Report

Scope of the Report

The global Soliris (Eculizumab) market size is predicted to grow from US$ 1,822 million in 2025 to US$ 1,215 million in 2032; it is expected to grow at a CAGR of -3.4% from 2026 to 2032.

Eculizumab, sold under the trade name Soliris, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PHN) and atypical hemolytic uremic syndrome (aHUS). It is a humanized monoclonal antibody functioning as a terminal complement inhibitor. In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death. Eculizumab was the first drug approved for each of its uses, and its approval was granted on the basis of small clinical trials.In 2025, global Soliris (Eculizumab) production reached approximately 339 k units.The average gross profit margin of this product is 65%.

The core opportunity for Soliris lies in the expanding clinical value of complement biology across rare diseases, autoimmune disorders, neuroimmunology, and kidney diseases. As physicians gain a deeper understanding of complement-mediated mechanisms, high-risk patients once scattered across hematology, nephrology, neurology, and intensive care are being identified earlier, supporting the expansion of targeted complement therapy from classic rare indications into broader immune-inflammatory settings. Corporate annual reports and regulatory documents show that Soliris has become a key benchmark for the commercialization of complement inhibitors. Its value is not limited to product revenue, but also extends to rare disease care pathways, patient screening, long-term treatment management, and global market access capabilities. For CEOs, marketing leaders, and investors, eculizumab represents an innovative biologics segment where high barriers, strong clinical value, and substantial willingness to pay coexist.The main challenges come from reimbursement pressure, competitive innovation, biosimilar entry, and safety management. As a high-value rare disease therapy, Soliris faces commercial constraints related to treatment cost and reimbursement access. At the same time, long-acting C5 inhibitors, subcutaneous complement drugs, alternative pathway inhibitors, and biosimilars are reshaping the competitive landscape. Clinically, complement inhibition requires strict management of risks such as meningococcal infection, meaning patients often require vaccination, risk education, and continuous monitoring. Because the target diseases involve limited patient populations, complex diagnostic pathways, and high demand for multidisciplinary collaboration, companies must continue investing in medical education, patient identification, real-world evidence, and payer communication to sustain lifecycle value.Downstream demand is shifting from rescue treatment for critically ill patients toward early diagnosis, early treatment, and long-term disease control. Hematology, nephrology, neurology, pediatrics, rheumatology, immunology, and rare disease centers now evaluate eculizumab not only through efficacy, but also through patient stratification, disease progression management, quality-of-life improvement, and long-term safety. As rare disease networks, genetic testing, complement testing, and multidisciplinary consultation systems mature, more potential patients may enter standardized treatment pathways. At the same time, patients and payers are placing greater emphasis on dosing convenience, treatment continuity, real-world benefit, and total healthcare cost control, encouraging companies to build a more complete ecosystem around drugs, diagnostics, follow-up, patient support, and access solutions.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Soliris (Eculizumab) market?

What factors are driving Soliris (Eculizumab) market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Soliris (Eculizumab) market opportunities vary by end market size?

How does Soliris (Eculizumab) break out by Type, by Application?

This report presents a comprehensive overview of the global Soliris (Eculizumab) market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Plasma Exchange
• Plasma Infusion

Segment by Complement Pathway Target

• Paroxysmal Nocturnal Hemoglobinuria
• Atypical Hemolytic Uremic Syndrome
• Other

Segment by Package

• Pre-filled Injections
• Vials

Segment by Application

• Hospital Infusion Therapy
• Long-term Maintenance Therapy
• Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Soliris (Eculizumab) market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Hospital Infusion Therapy, Long-term Maintenance Therapy, Other evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact